Solithromycin

Solithromycin is a macrolide antibiotic that is currently under development. It is a next-generation synthetic derivative of erythromycin and is designed to combat bacterial infections, including those caused by drug-resistant strains.

Etymology

The name "Solithromycin" is derived from the Latin word "solus," meaning "alone," and "thromycin," a common suffix for macrolide antibiotics. This name reflects the drug's unique mechanism of action, which allows it to work independently of other antibiotics.

Mechanism of Action

Solithromycin works by inhibiting protein synthesis in bacteria, thereby preventing their growth and reproduction. It binds to the bacterial ribosome, a cellular structure responsible for protein synthesis, and disrupts the process. This mechanism of action is similar to that of other macrolide antibiotics, but Solithromycin has been modified to overcome resistance mechanisms that have developed in bacteria against these older drugs.

Clinical Trials

Solithromycin has undergone several phases of clinical trials to evaluate its safety and efficacy. In Phase 3 trials, it was found to be as effective as moxifloxacin, a commonly used antibiotic, in treating community-acquired bacterial pneumonia. However, the drug has not yet received approval from the Food and Drug Administration (FDA) due to concerns about potential liver toxicity.

Related Terms

• Macrolide
• Antibiotic
• Erythromycin
• Protein synthesis
• Ribosome
• Clinical trials
• Moxifloxacin
• Food and Drug Administration

Solithromycin Resources
Latest articles Most recent articles Ongoing trials	Wikipedia